Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Abstract

BackgroundPazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice.MethodsA non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer.ResultsThe efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all.ConclusionsThis paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles.

Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma

“…Compared to the low-risk group, patients in the high-risk group had higher TIDE scores, suggesting that patients in the high-risk group may have a more limited response to ICI therapy. Previous clinical trials have confirmed that the benefits of pazopanib are more prominent in the low-risk group, which is consistent with our study (Méndez-Vidal et al, 2018). However, in the case of sorafenib, there is no evidence in the literature that it is more beneficial in the high-risk group, and the exact mechanism remains to be confirmed by more studies.…”

<p>Prognostic Significance of Preoperative Inflammatory Biomarkers and Traditional Clinical Parameters in Patients with Spinal Metastasis from Clear Cell Renal Cell Carcinoma: A Retrospective Study of 95 Patients in a Single Center</p>

“…With the understanding of molecular biology of RCC, several targeted agents inhibiting VEGF and mTOR signal transduction pathways such as Sunitinib, Sorafenib, Temsirolimus, and Pazopanib have been put into clinical practice. [33][34][35][36] Meanwhile, statistical results in our study revealed that targeted therapy significantly prolonged the OS of patients with spinal metastasis from CCRCC. Increasing clinical evidence has proven that targeted therapy can downsize the tumor size, control tumor progression, and improve OS, in view of Sunitinib and Sorafenib as the first-line or second-line treatment.…”

Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer

“…Pazopanib is a multi-kinase inhibitor medication indicated as a first-line treatment for adult patients with metastatic renal cell carcinoma (RCC). 1 It targets the vascular endothelial growth factor receptor, c-kit protein, and the platelet-derived growth factor receptor. Additionally, it strongly inhibits angiogenesis.…”